Skip to main content
OpenTrials
Completed

NCT Number: NCT03290300

Quality of Life Impact of Nasal Airway Treatment With Aerin Medical Device

Evaluation of long-term (5-year) quality of life after nasal airway obstruction treatment with the Aerin Vivaer Stylus

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Central California Clinical Research, Fresno, California, United States

Loading trial locations.

About this study

This is a prospective, non-randomized, multi-center follow-up study to collect long term quality of life (QOL) data on a cohort of patients who participated in the Aerin Medical TP258 study "A Prospective, Multi-Center, Non-Randomized Study to Evaluate Treatment of Nasal Airway Obstruction Using the Aerin Medical Device". The TP258 study followed subjects out to 26 weeks post-procedure. This QOL study will collect data at 12, 18, 24, 36, 48 and 60 months post-procedure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Received nasal obstruction treatment in Aerin Study TP 258

Exclusion criteria

  • Unwilling to participate in this long-term study

Treatment and study plan

Vivaer Stylus

Device

Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus

Other names: Aerin Medical Device

Primary outcomes

  1. Change From Baseline NOSE Score

    Time frame: Baseline, 12, 18, 24 months post-procedure

    Mean change in Nasal Obstruction Symptom Evaluation (NOSE) score from baseline. The NOSE scale ranges from 0 to 100, so a maximum change from baseline would be 100 points. A positive number reported for the change from baseline indicates an improved outcome.

  2. Change From Baseline NOSE Score - Long Term Extended Follow-up

    Time frame: Update to include Extended Follow up to 36-, 48- months post-procedure

    Mean change in Nasal Obstruction Symptom Evaluation (NOSE) score from baseline. The NOSE scale ranges from 0 to 100, so a maximum change from baseline would be 100 points. A positive number reported for the change from baseline indicates an improved outcome.

  3. Number and Percentage of Participants With Positive Response on Quality of Life Assessment Items

    Time frame: 12, 18, 24 months post-procedure

    This 21-item QOL scale was developed by Aerin Medical for this study to assess durability of symptom relief after treatment for nasal obstruction. Each item had 5 possible answers to convey the following responses: very positive, positive, neutral, negative and very negative. For questions 1-14, those who answered "agree or agree strongly" when prompted with "Compared to before I had the Aerin Medical Nasal Procedure, I have experienced..." were considered to have a positive response. For questions 15-18, those who answered "rarely/very rarely/never" when prompted with "Compared to before you had the procedure, how often did you suffer from the following conditions?..." were considered to have a positive response. For questions 19-21, those who answered "less or much less frequently" when prompted with "Compared to the time prior procedure, how often have you used the following to help you with nasal congestion/difficulty breathing?..." were considered to have a positive response.

Sponsors and collaborators

Lead sponsor

Aerin Medical

Industry

Registry information

Official study title

A Prospective, Multi-Center, Non-Randomized Study to Evaluate the Quality of Life Impact After Treatment of Nasal Airway Obstruction Using the Aerin Medical Vivaer Stylus

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Sep 21, 2017
Registry last updated
Feb 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.